Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová et al. · New England Journal of Medicine · 2006 · 3.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Filip Baert, Maja Noman, Séverine Vermeire et al. · New England Journal of Medicine · 2003 · 2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Michael E. Weinblatt, Edward Keystone, Daniel E. Furst et al. · Arthritis & Rheumatism · 2003 · 1.8K citations

Medicine, Pharmacology, Pharmacotherapy +15

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

Michael J. Elliott, Ravinder N. Maini, Marc Feldmann et al. · The Lancet · 1994 · 1.7K citations

Medicine, Clinical Sciences, Immunology +15

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

G. M. Bartelds · JAMA · 2011 · 767 citations · Full text

Life Sciences, Immunology, Pharmacology +17